These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 23683723

  • 1. The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165.
    Traub S, Morgner J, Martino MM, Höning S, Swartz MA, Wickström SA, Hubbell JA, Eming SA.
    Biomaterials; 2013 Aug; 34(24):5958-68. PubMed ID: 23683723
    [Abstract] [Full Text] [Related]

  • 2. Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2.
    Hall H, Hubbell JA.
    Microvasc Res; 2004 Nov; 68(3):169-78. PubMed ID: 15501236
    [Abstract] [Full Text] [Related]

  • 3. FAS1 domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and αvβ3 integrin.
    Nam JO, Son HN, Jun E, Cha K, Lee BH, Park RW, Kim IS.
    Mol Cancer Res; 2012 Aug; 10(8):1010-20. PubMed ID: 22710795
    [Abstract] [Full Text] [Related]

  • 4. Glycation of vitronectin inhibits VEGF-induced angiogenesis by uncoupling VEGF receptor-2-αvβ3 integrin cross-talk.
    Wang L, Zhang X, Pang N, Xiao L, Li Y, Chen N, Ren M, Deng X, Wu J.
    Cell Death Dis; 2015 Jun 25; 6(6):e1796. PubMed ID: 26111058
    [Abstract] [Full Text] [Related]

  • 5. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.
    Wu J, Strawn TL, Luo M, Wang L, Li R, Ren M, Xia J, Zhang Z, Ma W, Luo T, Lawrence DA, Fay WP.
    Arterioscler Thromb Vasc Biol; 2015 Jan 25; 35(1):111-20. PubMed ID: 25378411
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An engineered heparin-binding form of VEGF-E (hbVEGF-E). Biological effects in vitro and mobilizatiion of precursor cells.
    Heil M, Mitnacht-Krauss R, Issbrücker K, van den Heuvel J, Dehio C, Schaper W, Clauss M, Weich HA.
    Angiogenesis; 2003 Jan 25; 6(3):201-11. PubMed ID: 15041796
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Angiogenic response of endothelial cells to heparin-binding domain of fibronectin.
    Viji RI, Kumar VB, Kiran MS, Sudhakaran PR.
    Int J Biochem Cell Biol; 2008 Jan 25; 40(2):215-26. PubMed ID: 17766169
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Thyroid hormone induced angiogenesis through the integrin αvβ3/protein kinase D/histone deacetylase 5 signaling pathway.
    Liu X, Zheng N, Shi YN, Yuan J, Li L.
    J Mol Endocrinol; 2014 Jun 25; 52(3):245-54. PubMed ID: 24532656
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production.
    Huang YH, Wu MP, Pan SC, Su WC, Chen YW, Wu LW.
    Angiogenesis; 2013 Jan 25; 16(1):207-22. PubMed ID: 23086340
    [Abstract] [Full Text] [Related]

  • 20. Involvement of αvβ3 integrin in gremlin-induced angiogenesis.
    Ravelli C, Mitola S, Corsini M, Presta M.
    Angiogenesis; 2013 Jan 25; 16(1):235-43. PubMed ID: 23053782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.